| 1. |
|
|
| 2. |
- Ahlman, Håkan, 1947, et al.
(författare)
-
Growth regulation in carcinoid tumors.
- 1993
-
Ingår i: Endocrinology and metabolism clinics of North America. - 0889-8529. ; 22:4, s. 889-915
-
Forskningsöversikt (refereegranskat)abstract
- In hormone-producing tumors such as the carcinoids, overproduction of certain hormones may activate proto-oncogenes. Hormones, or growth factors, thus can be of importance for growth regulation. Information is presented on some growth factors and their receptors in this respect and on the involvement of gastrin and its receptor on tumor development in the experimental Mastomys model. The relevance of differential expression of cell adhesion molecules in endocrine tumors is discussed also.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Albrektsson, Tomas, 1945, et al.
(författare)
-
Direct bone anchorage of oral implants: clinical and experimental considerations of the concept of osseointegration.
- 1990
-
Ingår i: The International journal of prosthodontics. - 0893-2174. ; 3:1, s. 30-41
-
Forskningsöversikt (refereegranskat)abstract
- The term osseointegration is analyzed in relation to its theoretical and clinical definitions, and comparisons are made to other implant modalities. The term osseointegration has a clear clinical meaning, but there is doubt about its precise usage in an experimental setting. Clinically, an implant can be described as osseointegrated if there is no discernable movement when force is applied to the fixture. This is in contrast to implants surrounded by fibrous connective tissue, which move within soft tissue. Newly developed laboratory techniques may be used in the future to precisely characterize osseointegration in the laboratory.
|
|
| 6. |
|
|
| 7. |
- Albrektsson, Tomas, 1945, et al.
(författare)
-
State of the art in oral implants.
- 1991
-
Ingår i: Journal of clinical periodontology. - : Wiley. - 0303-6979 .- 1600-051X. ; 18:6, s. 474-81
-
Forskningsöversikt (refereegranskat)abstract
- Uncontrolled oral implant devices are still being widely used. The documentation of most oral implant systems is poorly backed up or not followed up for an adequate time period. Success rates are being quoted without reference to any defined success criteria. Frequently used oral implant designs such as the Core-Vent, IMZ and Calcitek hydroxyapatite coated implants are in neither case supported by any adequate clinical reports from minimally 5-years of follow-up. Other implant systems such as the ITI, some subperiosteal designs and the Tübingen implant demonstrate well-controlled and acceptable 5-year data but are not followed up in a sufficient number or have demonstrated less good results in the 10-year evaluation. The Small transosteal staple has been adequately reported for more than 10 years of follow-up, whereas the Brånemark implant is the only endosseous design that has demonstrated acceptable 15-year success rates.
|
|
| 8. |
- Basson, M D, et al.
(författare)
-
Biology and management of the midgut carcinoid.
- 1993
-
Ingår i: American journal of surgery. - 0002-9610. ; 165:2, s. 288-97
-
Forskningsöversikt (refereegranskat)abstract
- Midgut carcinoid tumors derive from gut entoderm. These tumors may cause a complex of symptoms comprising the carcinoid syndrome by secreting a wide variety of bioactive agents in addition to serotonin. Such symptoms generally follow metastases to the liver but may also occur in primary ovarian or retroperitoneal tumors. After localization and biochemical characterization, the bioactivity of these tumors should be blocked by octreotide, sometimes in combination with other pharmacologic antagonists, so that primary resection may be performed safely. If curative resection is impossible, then a cytoreductive management scheme should be employed that includes surgical debulking and hepatic arterial embolization, followed by palliation with octreotide.
|
|
| 9. |
- Bennich-Björkman, Li, et al.
(författare)
-
A creative university: is it possible?
- 1991
-
Ingår i: Studies of higher education and research, 1991:4. ; 1991:4
-
Forskningsöversikt (refereegranskat)
|
|
| 10. |
- Friman, Styrbjörn, 1948, et al.
(författare)
-
A possible role of ursodeoxycholic acid in liver transplantation.
- 1994
-
Ingår i: Scandinavian journal of gastroenterology. Supplement. - 0085-5928. ; 204, s. 62-4
-
Forskningsöversikt (refereegranskat)abstract
- There are many different causes of graft dysfunction and cholestasis after liver transplantation. These include non-primary function, preservation and reperfusion injury, acute rejection, artery thrombosis, drug toxicity, bile leakage, and bile duct stenosis. Medication with ursodeoxycholic acid (UDCA) has beneficial effects in different cholestatic conditions. The initial rationale for its use after liver transplantation was to alter the bile acid pool to a more atoxic composition, as liver transplantation can be associated with cholestasis and can stimulate the initial bile production. We have consecutively treated 41 patients with primary graft function with UDCA. During the first postoperative month, 17% of the UDCA treated patients had an episode of acute rejection compared with 75% of a historical control group of 8 patients. The results suggest that adjuvant treatment with UDCA reduces acute liver graft rejection. This has to be confirmed by controlled prospective trials; one is presently being carried out in the Nordic countries. Several studies have indicated an immunomodulating capacity of this bile acid and we have recently reported our results from a heart transplant model in the rat, where treatment with UDCA prolonged graft survival. Improvement in surgical technique and postoperative care as well as immunosuppressive treatment has improved the results of liver transplantation. Acute rejection is nowadays a dominating problem after liver transplantation and the inclusion of UDCA may reduce morbidity.
|
|
